Extracellular Vesicle Biomarkers for Breast Cancer Subtype Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing breast cancer subtypes are invasive, lack sensitivity, and cannot provide early detection or monitoring of disease progression, leading to ineffective treatments and increased recurrence rates.
Innovation Solution
A noninvasive method using extracellular vesicles (EVs) isolated from biofluids to identify differential expression of proteins or peptides, allowing for accurate breast cancer subtype diagnosis and treatment monitoring through a panel of biomarkers, including phosphorylated bruton tyrosine kinase (BTK) and acetylated myosin heavy chain 9 (MYH9).
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional biopsy and imaging techniques are used to diagnose breast cancer subtypes, then diagnostic accuracy can be achieved, but the procedures are invasive, time-consuming, and often delayed
Solution Approach 1:
The patent uses extracellular vesicles (EVs) as intermediary carriers that transport subtype-specific proteins and peptides from tumor cells into biofluids. By analyzing these EV-containing biofluids instead of performing invasive biopsies, the system achieves accurate subtype identification through a non-invasive liquid biopsy approach. The EVs serve as natural mediators that bridge the gap between tumor tissue and accessible body fluids.
Solution Approach 2:
The patent replaces mechanical tissue biopsy procedures with a biochemical analysis system. Instead of physically extracting and examining tissue samples through invasive procedures, the system uses biochemical assays to detect subtype-specific proteins and peptides within EVs in blood or other biofluids, thereby substituting mechanical intervention with chemical/biochemical detection methods.
2Measurement precision
If conventional biopsy methods are used, then tissue samples can be obtained for analysis, but the process is time-consuming and delays treatment initiation
Solution Approach 1:
The patent performs preliminary detection of breast cancer subtypes by analyzing EVs in biofluids before invasive biopsy procedures are undertaken. The system identifies subtype-specific proteins and peptides in circulating EVs, providing early diagnostic information that guides subsequent treatment decisions and eliminates the need for time-consuming biopsy wait periods.
Solution Approach 2:
The patent replaces time-consuming mechanical tissue biopsy and processing procedures with rapid biochemical analysis of EVs in liquid samples. The liquid biopsy approach allows for quicker sample preparation and analysis, significantly reducing the time from sample collection to diagnostic result while maintaining accurate subtype identification.
3Reliability
If triple negative breast cancer is diagnosed using conventional methods, then treatment can be planned, but the lack of early detection capability leads to poor prognosis
Solution Approach 1:
The patent applies local quality detection by identifying subtype-specific proteins and peptides within the EV population. For triple negative breast cancer, the system detects specific molecular signatures that distinguish TNBC from other subtypes, enabling targeted treatment planning. This localized molecular analysis within the heterogeneous EV population provides high sensitivity for early TNBC detection.
Solution Approach 2:
The patent replaces conventional imaging and physical examination methods with biochemical detection of EV markers. This substitution enables detection of TNBC at earlier stages when tumor burden is lower, as the EV-based assay can detect subtle molecular changes before they manifest as detectable imaging abnormalities or physical signs, thereby improving early detection sensitivity and prognosis.
Data Source
AI summary
Noninvasive methods of determining breast cancer subtype in a subject are provided that employ newly identified biomarkers. Said methods comprise isolating a population of extracellular vehicles in a biofluid sample of a subject and detecting differential expression in one or more proteins or peptides therein. Such differential expression is compared to one or more expression profiles within a panel of biomarkers, with each expression profile in the panel associated with a subtype of breast cancer. Also provided are kits for detecting a subtype of breast cancer and/or identifying the recurrence thereof, each comprising an antibody, aptamer, or other detection means against the aforesaid biomarkers. Methods for monitoring treatment efficacy in a subject experiencing breast cancer using the same platforms are also provided.